Intuitive Surgical stock holds above $372 as investors weigh recent valuation resets
Published on 08/30/2026 at 16:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical (US46120E6023) stock closed at $372.60 on Nasdaq as of August 29, 2026, marking a modest gain from a previous close of $367.07 in the prior session. Market data indicate that the shares later changed hands at $373.80 after the regular session, reflecting a move of -0.32% from that level.
Shares trade below earlier highs
Price data for August 29, 2026 show that Intuitive Surgical stock traded intraday between a low of $366.74 and a high of $373.39 before settling at $372.60 at the close. One quote overview places the stock well under a referenced 52-week high region, with a separate valuation screen indicating a last close of $367.07 and a fair value estimate of $248.93 for the shares. According to that same valuation screen, the implied downside from the recent $367.07 level to the modelled $211.59 target is 42%, underscoring how some quantitative models see limited upside for the current price level. A scoring list categorizes Intuitive Surgical within the S&P 500, highlighting that the stock still trades at a premium compared with its modelled intrinsic value.
For investors, the gap between the recent $372.60 close on August 29, 2026 and the modelled $211.59 level underlines how sentiment and growth expectations are embedded in the current valuation. The difference of $160.48 between the recent close and that modelled figure is substantial in absolute terms and may draw attention from both growth-oriented and valuation-focused investors who are assessing risk and reward at this stage of the cycle.
Fundamentals and growth backdrop
While the latest intraday quote from August 30, 2026 shows Intuitive Surgical trading at $545.39 in another consolidated view, the more detailed quote snapshots anchored to August 29, 2026 remain the clearest full-session reference point for current trading levels. This overview also indicates a daily move of 0.87% in the most recent 24-hour window, suggesting that the stock has continued to attract active trading interest into the current session.
Beyond the short-term moves, Intuitive Surgical continues to be profiled as a company that develops, manufactures, and markets systems that help physicians deliver minimally invasive care. An investment overview emphasizes that the company operates globally with a strong balance sheet and significant internally generated cash that can be used to fund research, development, and new procedure capabilities. That ample cash generation capacity supports ongoing innovation for its surgical platforms and instruments, a key factor underpinning long-term growth expectations even as valuation metrics fluctuate.
Historical reporting has highlighted how growth in procedure volumes and installed systems tends to support increasing recurring revenue from instruments, accessories, and service contracts. Although the specific most recent quarter figures are not detailed in the available quote and profile snapshots from the last 24 hours, the overall narrative continues to stress a combination of growing utilization and strong cash flow that has enabled the company to keep investing in new indications and system upgrades.
Valuation reset and risk signals
Despite the constructive long-term business profile, some recent commentary has underscored that the shares have undergone a notable valuation reset. One article notes that the stock recently closed at 321.40 in local currency terms on a European trading venue, marking a level 38% below a referenced 52-week high. That discrepancy illustrates how the stock has retreated from earlier peaks even as the company has reported strong cash flow metrics, reinforcing the idea that prior expectations had become stretched in relation to fundamentals.
The valuation screen that lists Intuitive Surgical in a large universe of S&P 500 stocks assigns a holding score of 3.24 and classifies the name under a strong sell recommendation at the modelled $211.59 price level. This scoring list uses a combination of quantitative factors to derive its rating, and the implied 42% downside from the last close of $367.07 to the modelled fair value suggests that, at least within this framework, the stock screens as expensive relative to its historical and peer-based benchmarks.
Viewed together, the recent 38% drawdown from a prior 52-week high on one venue and the 42% gap to a modelled fair value underline that valuation risk has become a central theme for Intuitive Surgical. For investors, the key question is whether continued expansion of the surgical installed base, along with recurring revenue from procedures and instruments, can justify maintaining the current premium multiple relative to the broader healthcare sector and the S&P 500 as reported in these models.
da Vinci platform remains core to growth
Intuitive Surgical's growth story continues to revolve around its flagship da Vinci robotic-assisted surgical platform, which supports a range of minimally invasive procedures across urology, gynecology, general surgery, and other specialties. The system combines robotic arms, 3D high-definition visualization, and specialized instruments, allowing surgeons to perform procedures through small incisions with enhanced precision and control.
Over time, the company has expanded the da Vinci platform with new generations of consoles, updated imaging, and instruments tailored to specific procedures, which in turn support increasing utilization. As hospitals and surgical centers adopt these systems, Intuitive Surgical benefits not only from the initial sale or placement of the platform but also from ongoing demand for single-use or limited-use instruments and accessories, as well as service contracts that help maintain and upgrade installed systems.
As a result, procedure growth and system placements form the backbone of the company’s recurring revenue model. Higher procedure volumes directly translate into greater demand for instruments and accessories, while a larger installed base supports multi-year service revenue and potential upgrades when customers move to newer system generations. This recurring element is a key reason why investors often assign the shares a premium valuation multiple relative to many capital equipment peers.
Intuitive Surgical stock and current trading context
In the latest consolidated snapshot, Intuitive Surgical stock is quoted at $545.39, with the price up 0.87% over the past 24 hours as of August 30, 2026. A recent intraday overview highlights this move, although the more detailed August 29, 2026 closing data of $372.60 along with the $373.80 after-hours mark and the prior $367.07 close provide a clearer basis for comparing modeled valuations and earlier price levels.
For retail investors tracking Intuitive Surgical, the interplay between robust cash-funded innovation and a share price that is both well below earlier peaks and yet still flagged as expensive by some valuation models is central. A closing level of $372.60 on August 29, 2026, combined with a 38% decline from a prior 52-week high on another venue and a modelled 42% downside to a $211.59 fair value estimate, summarizes the current push-pull between growth optimism and valuation risk. The stock remains a prominent healthcare constituent in the S&P 500, and the coming quarters of reported procedure growth, system placements, and cash flow trends will be critical for determining whether the present trading range proves sustainable.
Read more
More on Intuitive Surgical stock
Robotic surgery platform underpins business model
Intuitive Surgical's business model centers on enabling surgeons and hospitals to move complex procedures from open surgery to minimally invasive, robot-assisted techniques. The da Vinci system supports a broad range of procedures, and each installation is typically accompanied by significant training and support to help surgical teams adopt new techniques.
As the installed base grows, the company benefits from a recurring revenue stream as hospitals purchase instruments and accessories tailored to specific procedures and patients. Many of these components are single use or have limited lifespans, which ensures that higher procedure volumes translate into repeat revenue. Service agreements and software upgrades further enhance this recurring profile, and innovation in imaging, instrument design, and digital tools continues to open additional clinical indications.
Intuitive Surgical stock in one view
Putting these elements together, Intuitive Surgical stock currently reflects a balance between strong fundamentals and elevated expectations. A recent close of $372.60 on August 29, 2026, a subsequent after-hours mark of $373.80 with a -0.32% move, a prior close of $367.07, and a consolidated quote of $545.39 with a 0.87% daily gain frame the short-term trading picture. At the same time, the shares are indicated to be 38% below a prior 52-week high on one venue, while a quantitative model sees 42% downside from the recent $367.07 level to a $211.59 fair value estimate.
For investors, that combination of resilient cash-funded innovation, a growing minimally invasive surgery franchise, and a stock that has already experienced a sizable drawdown from previous peaks yet still screens as expensive in some models suggests a nuanced risk-reward profile. The next set of quarterly results and updated guidance on procedure growth, system placements, and cash generation will be watched closely to see whether they support the premium implied by current prices or prompt further reassessment of Intuitive Surgical's valuation within the healthcare sector.
Fact box
Company: Intuitive Surgical Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 29, 2026, close): $372.60 USD
Sector / Industry: Health care equipment
Index membership: S&P 500
